As part of the settlement, Bristol-Myers also owned up its role in depriving consumers of cheaper generic versions of its drugs Buspar and Taxol, the news source reported.
In 2007, Bristol-Myers faced allegations that it illegally concealed a side deal with the generic drugmaker Apotex to block the release of a generic form of Bristol’s blood-thinning drug Plavix. However, Bristol-Myers pleaded guilty to the charges and paid around $150 million to the states. The company also agreed to notify the states of patent litigation settlements with generic drug competitors.